choroidal neovascularization (CNV): Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by dreye

choroidal neovascularization (CNV) Introduction (What it is)

choroidal neovascularization (CNV) is the growth of abnormal new blood vessels beneath the retina.
These vessels come from the choroid, a vascular layer that normally nourishes the outer retina.
CNV is commonly discussed in retinal disease care, especially macular conditions that affect central vision.
It is used as a diagnosis and as a clinical concept to guide imaging, monitoring, and treatment planning.

Why choroidal neovascularization (CNV) used (Purpose / benefits)

In clinical practice, choroidal neovascularization (CNV) is “used” as a key diagnostic label because it identifies a specific mechanism of vision loss: leakage, bleeding, and scarring from abnormal vessels near the macula (the central retina responsible for fine detail). Recognizing CNV helps clinicians explain why symptoms such as new distortion (metamorphopsia), reduced central clarity, or a dark/blurred spot (central scotoma) may appear.

The main purpose of identifying CNV is to:

Detect a potentially vision-threatening process early. CNV can change quickly, and timely recognition supports appropriate monitoring and, when indicated, treatment.
Guide targeted testing. CNV is evaluated with retinal imaging that can show fluid, bleeding, and the abnormal vascular network.
Support treatment selection and follow-up planning. Many modern therapies are designed specifically to reduce CNV activity (for example, decreasing leakage and limiting damage to the light-sensing retina).
Standardize communication. The term allows ophthalmologists, optometrists, trainees, and patients to discuss the same underlying pathology in a consistent way.

Benefits of a clear CNV-based framework include more organized care pathways (screening → imaging → diagnosis → monitoring/treatment) and more precise documentation of disease activity over time.

Indications (When ophthalmologists or optometrists use it)

Clinicians use the diagnosis of choroidal neovascularization (CNV) and evaluate for it in scenarios such as:

New central visual distortion (straight lines look wavy) or sudden central blur
Unexplained decrease in best-corrected visual acuity, especially in one eye
New metamorphopsia on home monitoring tools (for example, grid-based checks)
Retinal exam showing subretinal fluid, hemorrhage, gray-green lesion, or lipid exudates near the macula
Known conditions associated with CNV, including:
Age-related macular degeneration (AMD)
Pathologic (high) myopia
Presumed ocular histoplasmosis syndrome (in some regions)
Inflammatory chorioretinal diseases (varies by clinician and case)
Macular disorders with breaks/defects in supporting layers (for example, certain dystrophies or trauma-related changes)
Follow-up of previously treated CNV to assess for recurrence or persistent activity
Pre- and post-treatment assessment to document response (anatomy and vision-related function)

Contraindications / when it’s NOT ideal

choroidal neovascularization (CNV) itself is not a medication or device, so “contraindications” mainly apply to specific tests or treatments used to evaluate or manage CNV. Situations where a CNV-focused approach may be less suitable, delayed, or replaced include:

Symptoms explained by a different diagnosis (for example, non-neovascular macular edema, central serous chorioretinopathy, or epiretinal membrane), where CNV is not the primary mechanism
Inactive or scarred CNV with no signs of ongoing leakage/hemorrhage on imaging, where management may lean toward observation/monitoring (varies by clinician and case)
When a planned test is not ideal:
Dye-based angiography may be avoided or modified in patients with certain dye allergies or other risk considerations (varies by clinician and case)
When a planned treatment is not ideal:
Intravitreal injection may be postponed in the presence of certain active eye infections or significant surface inflammation (clinician-dependent)
Some laser-based approaches may not be appropriate when the lesion involves the foveal center, due to risk of central vision damage (varies by lesion type and technology)
When overall goals of care differ, such as advanced disease with limited potential visual recovery, where the focus may be comfort, function, and realistic expectations (varies by clinician and case)

How it works (Mechanism / physiology)

choroidal neovascularization (CNV) occurs when the eye forms new, abnormal blood vessels that grow from the choroid toward the retina. The choroid is a vascular layer beneath the retinal pigment epithelium (RPE), which is a supportive cell layer essential for photoreceptor health.

Mechanism at a high level

A trigger (often chronic aging changes, inflammation, or mechanical stress) disrupts normal barriers and signaling between the retina, RPE, and choroid.
The eye increases pro-angiogenic signaling—commonly discussed in terms of vascular endothelial growth factor (VEGF)—which promotes new vessel formation.
These new vessels are typically fragile and leaky, leading to:
Fluid accumulation within/under the retina
Hemorrhage (bleeding)
Lipid exudation (deposits from chronic leakage)
Fibrosis/scarring, which can permanently affect central vision

Relevant anatomy

Macula/fovea: central retina for reading and facial recognition; involvement explains prominent central symptoms.
RPE and Bruch’s membrane: key support structures; disruption can enable vessel ingrowth.
Choriocapillaris/choroid: source of the abnormal vessels.

Onset, duration, and reversibility

CNV can appear subacutely or suddenly from a patient perspective, particularly when bleeding or fluid reaches the fovea. Duration varies widely depending on the underlying cause, lesion type, and response to therapy. CNV activity can sometimes be reduced or stabilized with treatment, but scarring and established retinal damage may not be fully reversible.

choroidal neovascularization (CNV) Procedure overview (How it’s applied)

choroidal neovascularization (CNV) is not a single procedure. It is a diagnosis that prompts a structured evaluation and management workflow. A typical high-level pathway includes:

Evaluation / exam – Symptom review (distortion, blur, central spot, color changes) – Vision testing and refraction as needed – Dilated retinal examination focused on the macula
Preparation – Baseline documentation of vision and symptoms – Imaging selection based on the clinical question and patient factors (varies by clinician and case)
Intervention / testing – Retinal imaging to confirm CNV activity and location:
- Optical coherence tomography (OCT) to look for fluid and structural changes
- Angiography (dye-based or non-dye methods) to characterize the neovascular network (when needed)
- If treatment is indicated, clinicians may consider options such as intravitreal anti-VEGF injections, photodynamic therapy, or laser in selected situations (choice varies by cause and lesion type)
Immediate checks – Post-test review of imaging findings – Discussion of what “active” vs “inactive” CNV means in general terms – Baseline comparison for future follow-up
Follow-up – Repeat symptom checks, vision measures, and imaging to track response or progression – Monitoring intervals are individualized (varies by clinician and case)

Types / variations

CNV is often classified by where the abnormal vessels grow relative to the RPE and retina, and by how it appears on imaging. Common frameworks include:

By anatomic location (often used with OCT/clinical correlation)

Type 1 (sub-RPE) CNV: vessels grow beneath the RPE. This can be associated with shallower fluid patterns and may be harder to see without imaging.
Type 2 (subretinal) CNV: vessels grow above the RPE in the subretinal space, often more directly affecting photoreceptors.
Type 3 neovascularization (retinal angiomatous proliferation, RAP): abnormal vascular growth originates within the retina and connects with deeper circulation; classification and terminology may vary by source.

By angiographic appearance (historically common with fluorescein angiography)

“Classic” CNV: more clearly defined leakage patterns.
“Occult” CNV: less well-defined leakage; can still be active and symptomatic.

By underlying cause (etiology-based)

Neovascular AMD-associated CNV: one of the most commonly discussed contexts in older adults.
Myopic CNV: associated with high myopia and structural stretching changes.
Inflammatory CNV: can occur with posterior uveitis or chorioretinal inflammation; workup and management may include addressing inflammation (varies by clinician and case).
CNV after trauma or retinal/RPE disruption: can occur near breaks in supporting layers.

By activity/status

Active CNV: signs of current leakage/hemorrhage and/or new symptoms.
Inactive/scarred CNV: more stable appearance with less evidence of ongoing leakage; long-term monitoring is often still relevant.

Pros and cons

Pros:

Identifies a specific, treatable mechanism of central vision loss in many cases
Supports early detection of macular disease activity through modern imaging
Enables targeted therapies aimed at reducing leakage and bleeding (therapy choice varies by cause)
Provides a common language for care coordination among providers
Helps structure follow-up around disease activity, not just symptoms
Encourages objective monitoring with OCT/angiography rather than relying only on visual acuity

Cons:

CNV can be complex to classify, and interpretation may vary by clinician and imaging modality
Some cases recur or persist, requiring ongoing monitoring over time
Even with control of leakage, scarring or atrophy may limit visual recovery in some patients
Diagnostic testing can involve multiple visits and repeated imaging
Treatments used for CNV (when indicated) may have risks and burdens (for example, repeated injections), which must be weighed individually
Symptoms can be subtle early on, so detection may be delayed without prompt evaluation

Aftercare & longevity

Because choroidal neovascularization (CNV) is a disease process rather than a one-time fix, “aftercare” usually means monitoring for activity and protecting visual function over time.

Key factors that influence outcomes and durability of control include:

Underlying cause of CNV: AMD-, myopia-, inflammation-, or trauma-related CNV can behave differently (varies by clinician and case).
Baseline lesion location: involvement of the foveal center can have a larger impact on fine-detail vision.
Amount of fluid/hemorrhage and duration before control: chronic fluid can be associated with more lasting retinal damage.
Consistency of follow-up: repeated imaging helps document whether CNV is active, stable, or recurring.
Coexisting retinal conditions: epiretinal membrane, geographic atrophy, diabetic macular changes, or glaucoma can affect visual function independently.
Treatment approach and response: some eyes respond quickly to certain therapies while others need adjustments (varies by clinician and case).
General eye health factors: ocular surface comfort and overall visual needs can influence how patients function day-to-day, even when CNV is anatomically stable.

Alternatives / comparisons

Management related to choroidal neovascularization (CNV) is often compared across a few broad approaches. The “best” option depends on cause, lesion type, location, and patient-specific considerations (varies by clinician and case).

Observation/monitoring vs active treatment

Observation/monitoring: may be used when CNV appears inactive, when symptoms are stable, or when imaging shows no treatable activity. This relies on follow-up exams and repeat imaging.
Active treatment: typically considered when there is evidence of active leakage/hemorrhage or meaningful recent change. The goal is to reduce ongoing damage rather than “cure” the underlying tendency.

Medication-based therapy vs procedure-based therapy

Anti-VEGF therapy (medication-based): commonly used to suppress signals that promote leakage and abnormal vessel growth. It is usually delivered by intravitreal injection in clinic settings.
Laser or photodynamic therapy (procedure-based): may be considered in selected CNV patterns and locations. These approaches can be limited by proximity to the fovea and by lesion characteristics.

Imaging strategies (noninvasive vs dye-based)

OCT (noninvasive): often the first-line tool for tracking retinal fluid and structure over time.
OCT angiography (non-dye): can visualize blood flow patterns and neovascular networks in many cases, though interpretation has limitations and can be affected by artifacts.
Fluorescein/ICG angiography (dye-based): can provide dynamic leakage and vascular detail when needed, but involves intravenous dye and additional considerations (varies by clinician and case).

choroidal neovascularization (CNV) Common questions (FAQ)

Q: Is choroidal neovascularization (CNV) the same thing as “wet macular degeneration”?
CNV is a process—abnormal new vessels growing near the retina. “Wet” (neovascular) age-related macular degeneration is one common condition in which CNV occurs, but CNV can also happen with high myopia, inflammation, or other macular disorders.

Q: What symptoms commonly suggest CNV?
People often report new wavy or distorted lines, a central blurry spot, reduced reading clarity, or sudden changes in one eye. Some cases are detected on imaging before symptoms become obvious, especially in monitored patients.

Q: How do clinicians confirm CNV?
Confirmation usually involves a dilated retinal exam plus imaging. OCT is commonly used to detect fluid and structural changes, and angiography (dye-based or non-dye) may be used to better characterize the abnormal vessels and activity.

Q: Does CNV hurt?
CNV itself is not typically described as painful. Discomfort, if present, is more likely related to associated conditions (such as surface irritation) or to specific diagnostic/treatment procedures rather than the CNV process.

Q: How long do CNV results last after treatment?
Duration varies widely. Some cases stabilize for long periods, while others show recurrence or require repeated treatment cycles; patterns differ by underlying cause and individual response (varies by clinician and case).

Q: Is treatment for CNV considered safe?
Commonly used treatments have well-known risk profiles, and safety discussions are individualized. In general, clinicians weigh potential benefits (reducing leakage/bleeding) against procedure-related and medication-related risks for each eye and each patient.

Q: What is the recovery like after common CNV treatments?
Recovery depends on the treatment type. Many clinic-based treatments allow return to routine activities relatively quickly, but short-term irritation or temporary blur can occur; follow-up timing and expectations vary by clinician and case.

Q: Can I drive or use screens if I have CNV?
Functional ability depends on the degree of central vision involvement and whether one or both eyes are affected. Clinicians typically assess visual acuity and visual function over time; day-to-day safety decisions vary by individual circumstances and local requirements.

Q: What does “active” vs “inactive” CNV mean?
“Active” generally means there are signs of ongoing leakage, bleeding, or new symptoms, often supported by OCT or angiography findings. “Inactive” suggests the lesion is stable without current leakage, sometimes with residual scarring or structural changes.

Q: Why are there so many follow-up visits and scans with CNV?
CNV can change over time, and imaging provides an objective way to track fluid, bleeding, and response. Repeat OCT (and sometimes angiography) helps clinicians distinguish stable anatomy from recurrence or incomplete control, which can affect next-step planning.